In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment until condition progression or perhaps the individuals are not able to tolerate the study drugs. 88 These preclinical studies deliver paradigms for upcoming clinical trials in AML, https://fernandodsfui.anchor-blog.com/12346437/rumored-buzz-on-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers